Clinical experience with cabazitaxel in patients with metastatic castrate resistant prostate cancer (ECLIPSE) (ELIPSE)

Study identification

• EU PAS number:
  EUPAS19826
• Study ID:
  19827
• Official title and acronym:
  Clinical experience with cabazitaxel in patients with metastatic castrate resistant prostate cancer (ECLIPSE) (ELIPSE)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  A multi-centre, observational, retrospective research study of patients with metastatic castrate resistant prostate cancer (mCRPC) who have received cabazitaxel in England. The primary objective is to describe the anti-cancer treatment pathways for patients who have received cabazitaxel following prior docetaxel treatment
• Study status:
  Finalised

Research institutions and networks

Institutions

Sanofi

Multiple centres: 5 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:25/03/2015

Study start date

Actual:27/03/2015

Date of final study report

Actual:07/11/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Sanofi

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable